Antimicrobial Agents and Chemotherapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Inhibition of < em > Pseudomonas aeruginosa < /em > quorum sensing by chemical induction of the MexEF-oprN efflux pump
Antimicrob Agents Chemother. 2024 Jan 8:e0138723. doi: 10.1128/aac.01387-23. Online ahead of print.ABSTRACTThe cell-to-cell communication system quorum sensing (QS), used by various pathogenic bacteria to synchronize gene expression and increase host invasion potentials, is studied as a potential target for persistent infection control. To search for novel molecules targeting the QS system in the Gram-negative opportunistic pathogen Pseudomonas aeruginosa, a chemical library consisting of 3,280 small compounds from LifeArc was screened. A series of 10 conjugated phenones that have not previously been reported to target bac...
Source: Antimicrobial Agents and Chemotherapy - January 8, 2024 Category: Microbiology Authors: Rasmus Kristensen Jens Bo Andersen Morten Rybtke Charlotte Uldahl Jansen Blaine Gabriel Fritz Rikke Overgaard Kiilerich Jesper Uhd Thomas Bjarnsholt Katrine Qvortrup Tim Tolker-Nielsen Michael Givskov Tim Holm Jakobsen Source Type: research
Structural role of K224 in taniborbactam inhibition of NDM-1
Antimicrob Agents Chemother. 2024 Jan 4:e0133223. doi: 10.1128/aac.01332-23. Online ahead of print.ABSTRACTTaniborbactam (TAN; VNRX-5133) is a novel bicyclic boronic acid β-lactamase inhibitor (BLI) being developed in combination with cefepime (FEP). TAN inhibits both serine and some metallo-β-lactamases. Previously, the substitution R228L in VIM-24 was shown to increase activity against oxyimino-cephalosporins like FEP and ceftazidime (CAZ). We hypothesized that substitutions at K224, the homologous position in NDM-1, could impact FEP/TAN resistance. To evaluate this, a library of codon-optimized NDM K224X clones for mi...
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: Daisuke Ono Maria F Mojica Christopher R Bethel Yoshikazu Ishii Salvador I Drusin Diego M Moreno Alejandro J Vila Robert A Bonomo Source Type: research
The metallo- β-lactamases strike back: emergence of taniborbactam escape variants
Antimicrob Agents Chemother. 2024 Jan 4:e0151023. doi: 10.1128/aac.01510-23. Online ahead of print.ABSTRACTMetallo-β-lactamases (MBLs) have evolved relatively rapidly to become an international public health threat. There are no clinically available β-lactamase inhibitors with activity against MBLs. This may change with the introduction of cefepime-taniborbactam. Herein, we review three manuscripts (S. I. Drusin, C. Le Terrier, L. Poirel, R. A. Bonomo, et al., Antimicrob Agents Chemother 68:e01168-23, 2024, https://doi.org/10.1128/aac.01168-23; C. Le Terrier, C. Viguier, P. Nordmann, A. J. Vila, and L. Poirel, Antimicrob...
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: Pranita D Tamma Jose M Munita Source Type: research
Retraction for Angelakis et al., "Abnormal Weight Gain and Gut Microbiota Modifications Are Side Effects of Long-Term Doxycycline and Hydroxychloroquine Treatment"
Antimicrob Agents Chemother. 2024 Jan 4:e0150923. doi: 10.1128/aac.01509-23. Online ahead of print.NO ABSTRACTPMID:38174939 | DOI:10.1128/aac.01509-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: American Society for Microbiology Source Type: research
Retraction for Angelakis et al., "Vitamin D and Prolonged Treatment with Photosensitivity-Associated Antibiotics"
Antimicrob Agents Chemother. 2024 Jan 4:e0150823. doi: 10.1128/aac.01508-23. Online ahead of print.NO ABSTRACTPMID:38174940 | DOI:10.1128/aac.01508-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: American Society for Microbiology Source Type: research
Structural role of K224 in taniborbactam inhibition of NDM-1
Antimicrob Agents Chemother. 2024 Jan 4:e0133223. doi: 10.1128/aac.01332-23. Online ahead of print.ABSTRACTTaniborbactam (TAN; VNRX-5133) is a novel bicyclic boronic acid β-lactamase inhibitor (BLI) being developed in combination with cefepime (FEP). TAN inhibits both serine and some metallo-β-lactamases. Previously, the substitution R228L in VIM-24 was shown to increase activity against oxyimino-cephalosporins like FEP and ceftazidime (CAZ). We hypothesized that substitutions at K224, the homologous position in NDM-1, could impact FEP/TAN resistance. To evaluate this, a library of codon-optimized NDM K224X clones for mi...
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: Daisuke Ono Maria F Mojica Christopher R Bethel Yoshikazu Ishii Salvador I Drusin Diego M Moreno Alejandro J Vila Robert A Bonomo Source Type: research
The metallo- β-lactamases strike back: emergence of taniborbactam escape variants
Antimicrob Agents Chemother. 2024 Jan 4:e0151023. doi: 10.1128/aac.01510-23. Online ahead of print.ABSTRACTMetallo-β-lactamases (MBLs) have evolved relatively rapidly to become an international public health threat. There are no clinically available β-lactamase inhibitors with activity against MBLs. This may change with the introduction of cefepime-taniborbactam. Herein, we review three manuscripts (S. I. Drusin, C. Le Terrier, L. Poirel, R. A. Bonomo, et al., Antimicrob Agents Chemother 68:e01168-23, 2024, https://doi.org/10.1128/aac.01168-23; C. Le Terrier, C. Viguier, P. Nordmann, A. J. Vila, and L. Poirel, Antimicrob...
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: Pranita D Tamma Jose M Munita Source Type: research
Retraction for Angelakis et al., "Abnormal Weight Gain and Gut Microbiota Modifications Are Side Effects of Long-Term Doxycycline and Hydroxychloroquine Treatment"
Antimicrob Agents Chemother. 2024 Jan 4:e0150923. doi: 10.1128/aac.01509-23. Online ahead of print.NO ABSTRACTPMID:38174939 | DOI:10.1128/aac.01509-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: American Society for Microbiology Source Type: research
Retraction for Angelakis et al., "Vitamin D and Prolonged Treatment with Photosensitivity-Associated Antibiotics"
Antimicrob Agents Chemother. 2024 Jan 4:e0150823. doi: 10.1128/aac.01508-23. Online ahead of print.NO ABSTRACTPMID:38174940 | DOI:10.1128/aac.01508-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: American Society for Microbiology Source Type: research
Structural role of K224 in taniborbactam inhibition of NDM-1
Antimicrob Agents Chemother. 2024 Jan 4:e0133223. doi: 10.1128/aac.01332-23. Online ahead of print.ABSTRACTTaniborbactam (TAN; VNRX-5133) is a novel bicyclic boronic acid β-lactamase inhibitor (BLI) being developed in combination with cefepime (FEP). TAN inhibits both serine and some metallo-β-lactamases. Previously, the substitution R228L in VIM-24 was shown to increase activity against oxyimino-cephalosporins like FEP and ceftazidime (CAZ). We hypothesized that substitutions at K224, the homologous position in NDM-1, could impact FEP/TAN resistance. To evaluate this, a library of codon-optimized NDM K224X clones for mi...
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: Daisuke Ono Maria F Mojica Christopher R Bethel Yoshikazu Ishii Salvador I Drusin Diego M Moreno Alejandro J Vila Robert A Bonomo Source Type: research
The metallo- β-lactamases strike back: emergence of taniborbactam escape variants
Antimicrob Agents Chemother. 2024 Jan 4:e0151023. doi: 10.1128/aac.01510-23. Online ahead of print.ABSTRACTMetallo-β-lactamases (MBLs) have evolved relatively rapidly to become an international public health threat. There are no clinically available β-lactamase inhibitors with activity against MBLs. This may change with the introduction of cefepime-taniborbactam. Herein, we review three manuscripts (S. I. Drusin, C. Le Terrier, L. Poirel, R. A. Bonomo, et al., Antimicrob Agents Chemother 68:e01168-23, 2024, https://doi.org/10.1128/aac.01168-23; C. Le Terrier, C. Viguier, P. Nordmann, A. J. Vila, and L. Poirel, Antimicrob...
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: Pranita D Tamma Jose M Munita Source Type: research
Retraction for Angelakis et al., "Abnormal Weight Gain and Gut Microbiota Modifications Are Side Effects of Long-Term Doxycycline and Hydroxychloroquine Treatment"
Antimicrob Agents Chemother. 2024 Jan 4:e0150923. doi: 10.1128/aac.01509-23. Online ahead of print.NO ABSTRACTPMID:38174939 | DOI:10.1128/aac.01509-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: American Society for Microbiology Source Type: research
Retraction for Angelakis et al., "Vitamin D and Prolonged Treatment with Photosensitivity-Associated Antibiotics"
Antimicrob Agents Chemother. 2024 Jan 4:e0150823. doi: 10.1128/aac.01508-23. Online ahead of print.NO ABSTRACTPMID:38174940 | DOI:10.1128/aac.01508-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - January 4, 2024 Category: Microbiology Authors: American Society for Microbiology Source Type: research
The metabolic slowdown caused by the deletion of < em > pspA < /em > accelerates protein aggregation during stationary phase facilitating antibiotic persistence
This study highlights the novel role of pspA in maintaining proteostasis, regulating dormancy depth, and affecting antibiotic persistence during stationary phase.PMID:38169282 | DOI:10.1128/aac.00937-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - January 3, 2024 Category: Microbiology Authors: Yingxing Li Xiao Chen Weili Zhang Kefan Fang Jingjing Tian Fangyuan Li Mingfei Han Jingjing Huang Tianshu Sun Fan Bai Mei Cheng Yingchun Xu Source Type: research
Doxycycline versus cephalexin treatment of presumed streptococcal skin and soft tissue infection among adults presenting to the emergency department
Antimicrob Agents Chemother. 2024 Jan 3:e0128223. doi: 10.1128/aac.01282-23. Online ahead of print.ABSTRACTAmong 100 propensity score-matched emergency department patients receiving ≤14 days doxycycline versus cephalexin monotherapy for outpatient treatment of nonpurulent (presumed streptococcal) skin and soft tissue infection, a low rate of 14-day clinical failure was observed [6% each group; odds ratio (OR), 1.34 (0.21-8.69); P = 0.745], defined as hospital admission, i.v. antibiotic therapy, or change in oral antibiotic. Doxycycline may represent a reasonable therapeutic alternative for this indication in regions with...
Source: Antimicrobial Agents and Chemotherapy - January 3, 2024 Category: Microbiology Authors: Eric Taylor Michael D Nailor Michelle Feider Shannon Sullivan Kellie J Goodlet Source Type: research